What is Biorce?
Biorce offers Aika, an AI-native platform engineered to expedite clinical trials. The platform streamlines protocol creation, feasibility analysis, and regulatory planning, empowering global clinical teams across the US, EU, and APAC. By enabling greater efficiency, reducing protocol amendments, and lowering operational costs, Biorce aims to accelerate patient access to novel treatments. The company's foundation is built by experts in clinical research and artificial intelligence, positioning it to redefine the landscape of drug development.
How much funding has Biorce raised?
Biorce has raised a total of $94.9M across 3 funding rounds:
Other Financing Round
$37M
Other Financing Round
$5.9M
Series A
$52M
Other Financing Round (2024): $37M with participation from YZR Capital, MSM fund (Mustard Seed Maze, and Plug and Play Tech Center
Other Financing Round (2025): $5.9M led by Norrsken Vc
Series A (2026): $52M supported by YZR Capital, MSM fund (Mustard Seed Maze, Norrsken Vc, and DST Global
Key Investors in Biorce
YZR Capital
YZR Capital is a venture capital firm specializing in early-stage investments within the HealthTech sector, focusing on European founders addressing complex healthcare challenges.
MSM fund (Mustard Seed Maze
MSM Impact VC Fund is an investment firm dedicated to supporting fast-growing European ventures that tackle social and environmental issues, aligning with Sustainable Development Goals.
Norrsken Vc
Norrsken VC is a leading early-stage impact investor in Europe, backing companies that address global challenges and demonstrate measurable impact alongside business growth.
What's next for Biorce?
With substantial enterprise-level backing, Biorce is poised for significant expansion and further development of its AI-driven clinical trial solutions. The recent strategic investment signals a new phase of growth, likely focused on scaling operations, enhancing platform capabilities, and broadening market reach. This capital infusion will be instrumental in solidifying Biorce's position as a leader in optimizing the drug development lifecycle, ultimately contributing to faster therapeutic innovation and improved patient outcomes.
See full Biorce company page
